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Abstract
The blue cone pathway is reported to be affected early in Parkinson’s disease (PD) and acquired type three (tritan) defects may
occur. Sixty-one patients attending a treatment and rehabilitation centre for PD were examined with clinical colour vision tests.
Seven of 13 patients, for whom the diagnosis of PD was equivocal or who had other medical conditions, were identified as having
tritan colour deficiency. Results for the remaining 44 PD patients were compared with 40 age matched controls. Ten PD patients
(22.7%) had tritan defects. Tritan defects were not found in the control group but performance on some tests was age related. We
conclude that clinical tests for tritan colour deficiency are unlikely to be helpful in identifying PD. © 1998 Elsevier Science Ltd.
All rights reserved.
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1. Introduction
Abnormal colour vision has been reported in several
studies of patients with Parkinson’s disease (PD). Meth-
ods of assessment have included clinical tests, such as
the Farnsworth–Munsell 100 hue test (FM 100 hue
test), and computerised techniques to measure colour
thresholds and colour contrast sensitivity. Significantly
higher FM 100 hue error scores have been found in ‘de
novo’ PD patients, compared with age matched con-
trols [1]. Error scores have been found to correlate with
duration of the disease and with it’s severity according
to the Hoehn–Yahr staging and the Unified Parkin-
son’s Disease Rating Scale (UPDRS) [2,3]. The FM 100
hue error scores were also found to decrease signifi-
cantly when patients, who had been deprived of treat-
ment for 12 h, were re-examined 30 min after receiving
individual L-Dopa medication [4]. The FM 100 hue
plots generally showed poor overall hue discrimination
both before and after treatment. However, Price et al.
[3] found that six out of 35 patients obtained a tritan
axis of confusion and that two patients obtained a
red-green axis. Poor overall hue discrimination was
found with the Lanthony desaturated D15 test by Haug
et al. [5] although colour contrast sensitivity measure-
ments showed specifically poorer performance along a
tritan axis. Tritan contrast thresholds, for the detection
of motion, were also found to be significantly raised for
both foveal and parafoveal stimuli [6]. Similar results,
in which psychophysical tests show tritan deficits and
clinical tests demonstrate poor overall hue discrimina-
tion, have been reported for patients with advanced
diabetic retinopathy and are typical of acquired type
three colour deficiency [7].
Dopaminergic neurons degenerate in the retina as
well as in the brainstem of PD patients. Short wave-
length (blue) receptors are sparse in the central retina
and the short wavelength mechanism is particularly
vulnerable to acquired damage. In consequence, But-
tner et al. [1] have suggested that an acquired type three
(tritan) defect may originate at the retinal level as an
early diagnostic sign of PD. Colour vision screening,
with tritan tests, may therefore be helpful in identifying
and monitoring patients with idiopathic PD. The FM
100 hue test is not the test of choice because it is not a
dedicated tritan screening test and is relatively time
consuming. The aim of the present study is to establish
whether other more rapid clinical tests for tritan defects* Corresponding author. Fax: 44 171 4778355.
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are effective in showing acquired colour deficiency in
PD patients.
2. Subjects and methods
Colour vision was assessed in 61 patients (mean age
63.5918.9 years) attending a treatment and rehabilita-
tion centre for patients with Parkinson’s disease (the
Paracelsus Elena Klinik, Kassel). Medical records of
the PD patients were consulted at the end of the study.
The results of 13 patients (mean age 72.099.9 years)
for whom the diagnosis of PD was equivocal or who
had other medical conditions, which might lead to
acquired colour deficiency, were excluded from the
main analysis and test results evaluated separately.
These were five diabetic patients, five symptomatic pa-
tients not confirmed as PD, two patients with glaucoma
and one patient receiving anti-epileptic medication. The
results of four male patients with congenital red-green
(R:G) colour deficiency were also excluded. Results
were analysed for the remaining 44 PD patients, one of
whom was aphakic (23 male and 21 female, mean age
68.597.7 years).
The examination consisted of a battery of pseu-
doisochromatic plates and hue discrimination tests able
to identify both R:G and tritan defects. Individually
each test was much less time consuming and easier to
complete than the FM 100 hue test. Pseudoisochro-
matic tests involve the detection and verbal identifica-
tion of a coloured figure. In hue discrimination tests the
patient arranges small coloured samples into a natural
hue sequence. The tests included were as follows:
1. A composite pseudoisochromatic test consisting of
13 plates: Seven numeral plates from the Ishihara
test for the detection of R:G colour deficiency, the
New City University Tritan test (five plates) and the
Farnsworth F2 plate. The seven Ishihara plates were
the introductory plate, two plates with transforma-
tion designs (plates three and six from the 38 plate
edition), two plates with vanishing designs (plates 11
and 14) and one protan:deutan classification plate
(plate 22). The numerals are of serif design. The
City tritan test has five plates with vanishing designs
containing geometric symbols [8]. Circles, crosses
and triangles are used. Three plates have small
colour differences for tritan screening and two
plates have large colour differences to identify
severe tritan deficiency.
2. The SPP2 plates. All these plates have vanishing
designs containing numerals. There are 11 designs
for tritan defects and five designs for R:G defects.
The numerals have a square box-shaped design sim-
ilar to that found on computer screens.
3. The Lanthony Tritan Album. The Tritan Album
has an introductory plate and five plates, with
ranked colour difference steps, for identifying and
grading tritan colour deficiency. Errors on two, or
more, plates identifies severe tritan deficiency. Each
plate has a square of grey dots with violet dots in
one corner. The subject has to locate the position of
the coloured dots.
4. The T16 test. The T16 test is similar to the
Farnsworth D15 test but has more scope for identi-
fying tritan defects. The Munsell colours have value
five and chroma of either four, six or eight [9].
Tritan colour deficiency, R:G colour deficiency or
poor overall hue discrimination is identified from
the results diagram.
5. The Adams desaturated D15 test. The Munsell hues
are the same as those of the Farnsworth D15 but
the samples have value five and chroma two. Tritan
colour deficiency, R:G colour deficiency, or poor
overall hue discrimination can be identified from the
results diagram.
6. Sahlgren’s Saturation test (SST). This test consists
of ten colour samples, two greys, four blue-greens
and four violets in graded saturation steps. The
subject has to select samples which appear to be
neither bluish or greenish (grey). The test is scored.
An error score of 15 is borderline and a score of 20,
or more, is abnormal.
Tests were illuminated with the Richmond 1338R
True Daylight Illuminator. The mean illuminance was
250 lux.
Forty age-matched subjects with no ocular or general
pathology (mean age 68.099.1 years) were examined
with the same test battery in the School of Optometry
Table 1
Percentage failure rate of 44 PD patients and 40 age-matched normal subjects on clinical colour vision tests designed to identify tritan colour
deficiency
Percentage of normal subjects failingTest Percentage of Parkinson’s disease patients failing
13City University Tritan plates 23
SPP2 (Tritan designs) 14 70
16Lanthony Tritan Album 5
16Sahlgren’s Saturation Test 0
T16 1554
4395Adams D15
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Table 2
Test results for four patients with Parkinson’s disease with other medical conditions and three symptomatic patients not confirmed as PD who
have acquired type three (tritan) colour deficiency
M:F Age Tritan plate SPP2 tritan Tritan albumMedical condi- SST score T16 result Adams. D15 Diagnosis
tion errors resulterrorserrors
PD and diabetes
67 5a 7bHG 5M 80 Tritan Tritan Severe tritan
61 1PB 1M 1 20 Tritan — Slight tritan
75 2 0 1 10 TritanM TritanWK Slight tritan
PD and epilepsy
82 5a 3b 1MM 20F Tritanb Tritanb Severe tritan
Symptomatic (PD not confirmed)
84 5a 8bGI 5F 40 Tritanb Tritanb Severe tritan
FV 76F 3a 4b 2 10 Tritanb Tritanb Severe tritan
59 1 0 0F 30EM Tritanb Tritanb Slight tritan
—, did not complete.
a Also fail F2 plate.
b Also R:G errors.
at the University of New South Wales. In this case
illumination was provided by screened GE fluorescent
daylight tubes with a correlated colour temperature of
5500 K, rated category D when assessed in accordance
with C.I.E. Publication 51. The mean illuminance was
240 lux.
Tests were carried out binocularly and normally took
between 10 and 15 min to complete. The visual acuity
of all the subjects was 6:12 or better.
Verbal test instructions were given in German to
patients in the Paracelsus–Elena Klinik and in English
at the School of Optometry in the University of New
South Wales. Examinations were supervised by the
same person in both locations in order to minimise any
possible bias in administration.
3. Results
The percentage failure rate for 44 PD subjects and
40 age-matched normals is shown in Table 1. Ninety
five percent of patients and 43% of normals made
errors on the Adams D15 test. In consequence, the
criterion used for the diagnosis of acquired type
three (tritan) colour deficiency was that tritan errors
must be made on at least two other tests in addition
to the D15. The diagnosis of acquired colour deficiency
was not therefore based exclusively on failure of hue
discrimination tests. Severity of colour deficiency
was determined by errors on tritan grading plates and:
or the number of errors on the Lanthony Tritan Al-
bum. No errors were made on the Ishihara plates
except by patients with congenital red-green colour
deficiency.
3.1. Excluded patients
Seven of the 13 patients excluded from the main
analysis were found to have tritan colour deficiency
(Table 2).
Three of the five diabetic patients had tritan defects.
The defect was severe in one patient (HG) and slight in
two. HG’s colour deficiency was identified by all six
tests. He could not interpret any of the plates in the
City test or the Lanthony Tritan Album, and failed
eight of the 11 tritan designs in the SPP2 test. Tritan
axes of confusion were obtained with the T16 and the
Adams D15. A score of 80 was obtained on Sahlgren’s
saturation test. One diabetic patient passed all the tests
and one failed the Adams D15 only.
Three of the five patients with symptomatic disease
were found to have tritan defects; one patient had slight
colour deficiency and two patients severe colour defi-
ciency. The results for patient GI were similar to those
of HG except that errors were made on R:G designs of
the SPP2 test in addition to tritan errors and the error
score obtained on Sahlgren’s test was 40. R:G errors as
well as tritan errors were also made on hue discrimina-
tion tests. One symptomatic patient passed all the tests
and one failed the Adams D15 only.
The patient being treated with anti-epileptic medica-
tion (MM) also had severe tritan colour deficiency.
MM made tritan errors on all six tests but failed fewer
pseudoisochromatic plates than HG and GI. She failed
only one plate of the Lanthony Tritan Album and
could not interpret three R:G designs as well as three
tritan designs of the SPP2 plates. An error score of 20
was obtained with Sahlgren’s test. R:G and tritan
errors were made on hue discrimination tests.
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Table 3
Test results for ten patients with Parkinson’s disease diagnosed as having acquired type 3 (tritan) colour deficiency
Age Tritan platePatient SPP2 tritan DiagnosisTritan album SST score T16 result Adams D15M:F
errorserrors errors result
79 3 2 5 15 Tritan TritanAB Severe tritanF
78 5a 4 0F 5EK Tritan Tritan Severe tritan
76AU 3M 1 0 5 Pass Tritan Moderate tritan
72 3 2 0F 20GB Tritan Tritan Moderate tritan
FAG 68 2a 2 0 10 Tritanb Tritan Slight tritan
FEW 61 2 1 0 15 Tritan Tritan Slight tritan
80 3 0 0F 0JW Tritan Tritan Slight tritan
69 1 0 1HM 20M Pass Tritan Slight tritan
67 1 1 0M 10HZ Tritan Tritan Slight tritan
75WS 0M 0 1 20 Tritan Tritan Slight tritan
a Also fail F2 plate.
b Also R:G errors.
Neither of the patients with glaucoma nor any of the
patients with congenital R:G colour deficiency made
errors indicating tritan colour deficiency. One patient
with glaucoma failed the Adams D15.
3.2. PD patients
Ten of the 44 PD patients (22.7%) were identified as
having tritan colour deficiency (Table 3). Two patients
had severe colour deficiency, two had moderate defi-
ciency and six had slight colour deficiency. The mean age
of these patients was 72.694.4 years.
Two patients had severe tritan deficiency but neither
failed all the tests. AB failed the tritan screening plates
in the City test and could not interpret any of the tritan
plates in the Lanthony Tritan Album. She failed three
tritan designs in the SPP2 test and obtained tritan results
for both hue discrimination tests. A borderline result was
obtained with Sahlgren’s test. The second patient with
severe tritan colour deficiency, EK, failed the F2 plate
and both screening and grading tritan plates in the City
test. EK failed four tritan plates in the SPP2 test but was
able to pass the Lanthony Album, Sahlgren’s test and
the T16 test. Two patients, AU and GB, made mistakes
on all the tests except the Lanthony Tritan Album and
were considered to have moderate tritan deficiency. Six
PD patients were found to have slight tritan colour
deficiency. All these patients failed the Adams desatu-
rated D15 test and two other tests. Five patients failed
the City test, five failed the T16, three failed the SPP2,
two recorded single errors on the Lanthony Album and
two patients failed Sahlgren’s test.
Of the remaining 34 PD patients, three patients com-
pleted all the tests without error; 22 patients made
mistakes on the Adams desaturated D15 and failed one
other test, nine patients failed the D15 only.
In total, 41 of the 44 patients with confirmed PD
patients failed the Adams D15, 12 patients obtaining a
diagnostic tritan result and 29 patients showing poor
overall hue discrimination. In comparison 19 patients
failed the T16 test, 12 obtaining a tritan result and seven
patients showing poor overall hue discrimination. Only
four patients obtained tritan results on both tests.
A smaller number of PD patients made errors on
pseudoisochromatic plates. Ten patients made mistakes
on screening plates of the City test and two patients
failed the F2 plate. Seven patients made errors on the
Lanthony Tritan Album and seven patients were
classified as having abnormal colour vision with
Sahlgren’s Saturation Test. Six patients made tritan
errors on the SPP2 test. The aphakic patient made errors
on the D15 and T16 tests.
3.3. Normal subjects
Only eight of the 40 normal subjects examined passed
all the tests without error. All these subjects were under
63 years of age. The remaining subjects made random
errors on at least one test. These errors tended to be
‘design specific’ and related to the visual task needed for
the test. The SPP2 numerals were found to be much
more difficult for the (British) normal subjects to identify
verbally compared with the (German) PD patients. This
is possibly due to the greater familiarity with boxed
numeral shapes used in German literature. Some sub-
jects in both groups found it consistently difficult to
name triangles compared with circles or crosses. No
subject was considered to have tritan colour deficiency.
Twenty-eight subjects (70%) made errors on the SPP2
plates which included R:G as well as tritan errors. No
subject failed two other tests in addition to the SPP2.
Seventeen subjects (43%) made errors on the Adams D15
test but in only six cases were these diagnostic tritan
errors. Six subjects made errors on the T16 test. Five
subjects made a single error on tritan screening plates
and two made a single error on the Lanthony Tritan
Album. No normal subject failed, or was borderline, on
Salhgren’s test.
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4. Discussion
The present results confirm those of Kupersmith et
al. [10] that R:G colour deficiency is not identified with
pseudoisochromatic plates in PD. Identification of tri-
tan colour deficiency in older patients is masked by
physiological changes in the eye media with age. The
present results show that age related errors can be
anticipated on both the SPP2 plates and the Adams
D15. This is partly attributed to the use of desaturated
colours with small colour differences. Haug et al. [5]
found that PD patients showed poor hue discrimination
with the Lanthony desaturated D15 test (Munsell value
eight and chroma two). The Lanthony test has very
desaturated colours and is difficult for young normal
subjects to complete without error at the illumination
levels used in this study. The Adams test presents a
more appropriate level of difficulty. Although 95% of
PD patients failed the Adams test, 43% of normals also
failed. The T16 test is designed specifically to identify
tritans and contains more saturated colours than the
Adams test. The T16 was failed by 54% of PD patients
and by 15% of normals. Neither test is therefore very
efficient in separating PD patients and normal age
matched controls. Older subjects often found the visual
task of ordering colours difficult to comprehend ini-
tially and manipulating small samples caused particular
problems for PD patients with tremor. Tremor tended
to increase with the concentration needed to arrange
the colours. Pseudoisochromatic tests are easy to under-
stand and tritan tests which employ moderate or large
colour differences, such as the City tritan test and the
Lanthony Album, were found to be less affected by age.
However isolated design specific errors, depending on
the familiarity of the contained figure, were made by
both PD patients and normals. The figure designs con-
tain numerals in two different fonts, as well as geomet-
ric symbols, and some subjects preferred to draw over
the design rather than attempt a verbal identification.
Of the 61 patients examined eight were found to have
either severe or moderate type three (tritan) colour
deficiency. Two of these patients had additional pathol-
ogy and the diagnosis of PD was equivocal in two.
These results suggest that between 7 and 13% of PD
patients, undergoing treatment, have significant tritan
colour vision deficits. In all ten PD patients (22.7%)
have some degree of aquired colour deficiency. Most
patients received medication at intervals throughout the
day and it was not possible to co-ordinate the colour
vision examination to take place either immediately
before medication or at a set interval following medica-
tion. In consequence it was not possible to assess the
effect of treatment.
Acquired type three (tritan) deficiency is often char-
acterised by poor overall hue discrimination. In this
case both tritan and R:G diagnostic errors may occur
and, if desaturated colours are used, it is difficult to
distinguish pathological and physiological changes with
age. Results obtained with tests based on different
design principles, employing a variety of visual tasks,
are not necessarily expected to agree precisely. Individ-
ual clinical tests tend to have either low sensitivity or
low specificity for identifying acquired colour deficiency
in PD patients. All the tests included in the present
study have potential for identifying acquired type three
(tritan) colour deficiency confirmed by the results ob-
tained by PD patients with other medical conditions.
The results for three patients (particularly HG) were
typical of severe acquired colour deficiency. In contrast
only two of 44 PD patients, without other pathology,
had severe acquired colour deficiency. The absence of
clear tritan colour deficiency in PD patients strongly
suggests that previously reported colour vision deficits
originate in the visual pathway rather than at the
retinal level and it is unlikely that clinical tests have a
useful role in monitoring the effects of treatment in PD.
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